← Oncology Approval Tracker

FDA DECISION ·

Keytruda + trastuzumab + chemotherapy

pembrolizumab with trastuzumab and fluoropyrimidine- and platinum-based chemotherapy · Merck

Accelerated approvalNew or expanded indicationGastric and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Mar 19, 2025

FDA Project Confirm ↗

APPROVED USE

What FDA approved

First-line therapy for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. The later traditional approval limits use to PD-L1 CPS of at least 1.

LAMPGEN ANALYSIS

Why it matters

The 2021 accelerated action combined checkpoint inhibition with HER2-directed treatment and chemotherapy. The 2025 conversion narrowed the biomarker population.

What research teams should watch

Preserve HER2, PD-L1 and treatment dates when comparing cohorts before and after the label changes.

PRIMARY RECORDS

Sources